Researchers have developed novel oral films that can be placed on the inner cheek of the mouth to release drugs into the bloodstream instead of swallowing bulky tablets. This simple and pain-free method is now being commercialized.
Researchers from NUS Department of Pharmacy - Ms Chua Qi Shan (left), Associate Professor Chan Sui Yung (centre), and Dr Tan Poh Leng (right) - showing samples of the oral films that they have developed for painless, efficient and discreet drug delivery.
(Source: NUS)
Queenstown/Singapore – Conventional ways of administering medication – by swallowing tablets, consuming bitter syrups, injections or rectal insertions – could be distressing and unpleasant for some patients, especially young children or the elderly. A team of researchers led by Associate Professor Chan Sui Yung, Honorary Fellow at the Department of Pharmacy under the Faculty of Science at the National University of Singapore (NUS), has recently developed easy-to-use oral films that enable painless, efficient, and discreet drug administration.
This patient-friendly drug delivery method is now being commercialized through an NUS start-up Pharlyfe+ founded by Assoc Prof Chan and her students, Dr. Tan Poh Leng and Chua Qi Shan, who are the Business Lead and Clinical Lead of Pharlyfe+ respectively. The start-up is supported by NUS Graduate Research Innovation Programme (Grip), a venture creation programme which encourages NUS researchers and postgraduate students to start their own deep-tech companies.
The novel oral film releases drugs into the bloodstream via the mucosal membrane – the moist, inner lining of the mouth. Each oral film can be easily placed onto the inner cheek of the patient’s mouth, and medication will be released into the bloodstream over a pre-determined period of time.
This method of medication administration reduces the risk of choking, aspiration, and rejection. Moreover, the manufacturing method of the films eliminates dosing errors commonly associated with multi-dose bottles of liquid medicine.
Patient-centric, personalized drug delivery
Assoc Prof Chan said, “Our oral film marks a significant milestone in patient-centric and personalized medicine, offering a safer and eco-friendly alternative to traditional drug delivery methods. The film is very easy to use, so patients are empowered with dignity and independence in managing their treatment from the comfort of their homes. We look forward to collaborating with healthcare providers to develop and apply the oral films to improve patient care and treatment outcomes.”
Each oral film is very thin and round, and it comes in two sizes – 10- and 20-cent coin sizes – making it convenient to be carried around, distributed, or stored in larger quantities at healthcare institutions. Additionally, the films have a low water content, so they have a longer shelf life compared to compounded liquid medicines, hence they could be a reliable option for patients and healthcare providers.
The team’s first oral film product will focus on administering medications for patients suffering from end-of-life delirium and anxiety. The process of treating end-of-life symptoms can be painful as injections are often administered, when comfort care should be the top priority. “We hope that our solution can help improve the quality of care for these patients,” said Chua. The film may also benefit epileptic patients, with more studies underway.
A sustainable and cost-effective solution
The oral films are easy to produce. Each film comprises a customized premix of ingredients formulated for a specific medication. These ingredients are added to the drug solution, and an accurate volume of the required drug dosage is pipetted onto a mold. The resulting mixture is dried using a light-duty oven. This method of production uses fewer ingredients and smaller quantities of materials compared to traditional drug-delivery methods, particularly those that require costly, single-use applicators and devices such as syringes, needles, inhalers, and auto-injectors.
Without the need for bulky packaging, or the use of dosage-measuring devices such as syringes and spoons, which are made of plastic and supplied with each treatment course, the oral film is therefore more environmentally friendly and cost-effective.
Dr. Tan, whose PhD work focused on oral films, explained, “Our films are compounded on-demand to ensure that they contain the precise dosage and strength for each patient, and then sealed in minimal packaging. This streamlined approach to drug delivery not only saves time and money, but also reduces the environmental impact.”
Associate Professor Lita Chew, President of the Singapore Pharmacy Council, and a clinical faculty member at NUS Pharmacy who is not involved in the start-up, said, “The innovative approach to compound prescribed drug into oral film is a game-changer for delivery of medication, especially to segment of populations that have difficulty taking traditional dosage forms such as tablets, capsules, syrups and injections. I look forward to the day when the oral film premix kits can be extended to home use, like the many self-test kits on pharmacy shelves.”
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.
Future plans
The NUS team has filed a provisional patent for this innovative approach. Currently, the researchers are developing and evaluating their film products for different medications, such as for antidotes, general medication, and medication for pets, to prepare for regulatory filing in Singapore and the United States of America.
They plan to supply the premix of the oral film to healthcare institutions for pharmacists and clinic staff to prepare oral film medications when doctors prescribe them to patients. HCA Hospice Care is one of the healthcare institutions whom they partnered for the initial launch of their ready-to-market package comprising facilities set-up and staff training for preparing film medicines using Pharlyfe+ premix.
The team also aims to work with investors, regulatory experts, contract manufacturers, and pharmaceutical marketers to commercialize their technology.